The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Gelatinase B–deficient Mice Are Resistant to Experimental Bullous Pemphigoid
Open accessAbstract
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease characterized by deposition of autoantibodies at the basement membrane zone. In an experimental BP model in mice, the subepidermal blistering is mediated by antibodies directed against the hemidesmosomal protein BP180 (collagen XVII, BPAG2), and depends on complement activation and neutrophil infiltration. Gelatinase B is present in BP blister fluid and can cleave BP180. In this study we investigated the role of gelatinase B in the immunopathogenesis of experimental BP using mice containing targeted disruption of the gelatinase B (MMP-9, 92 kD gelatinase) gene. Gelatinase B–deficient mice were resistant to the blistering effect of intracutaneous anti-mBP180 antibodies, although these mice showed deposition of autoantibodies at the basement membrane zone and neutrophil recruitment to the skin comparable to that observed in the control mice. Interleukin 8 given intradermally concomitantly with pathogenic anti-mBP180 elicited a significant neutrophil recruitment into the skin in gelatinase B–deficient mice, but blistering did not occur. However, gelatinase B–deficient mice reconstituted with neutrophils from normal mice developed blistering in response to anti-mBP180 antibodies. These results implicate neutrophil-derived gelatinase B in the pathogenesis of experimental BP and might lead to novel therapeutic strategies for BP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Destruction by Neutrophils
Epstein, F. H., & Weiss, S. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902093200606 · Cited by 3,950
Cited by
Nagase, H., & Woessner, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21491 · Cited by 3,912
Matrix metalloproteinases as modulators of inflammation and innate immunity
Parks, W. C., Wilson, C. L., & López-Boado, Y. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1418 · Cited by 1,929
Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9)
Van den Steen, P. E., Dubois, B., Nelissen, I., Rudd, P. M., Dwek, R. A., & Opdenakker, G. (2002) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230290771546 · Cited by 946
Pyo, R., Lee, J. K., Shipley, J. M., Curci, J. A., Mao, D., Ziporin, S. J., Ennis, T. L., Shapiro, S. D., Senior, R. M., & Thompson, R. W. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8931 · Cited by 830
Self-citationDucharme, A., Frantz, S., Aikawa, M., Rabkin, E., Lindsey, M., Rohde, L. E., Schoen, F. J., Kelly, R. A., Werb, Z., Libby, P., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8768 · Cited by 808
Self-citationMatrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Hu, J., Van den Steen, P. E., Sang, Q.-X. A., & Opdenakker, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2308 · Cited by 795
Vandooren, J., Van den Steen, P. E., & Opdenakker, G. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.770819 · Cited by 766
Biological role of matrix metalloproteinases: a critical balance
Löffek, S., Schilling, O., & Franzke, C.-W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00146510 · Cited by 756
Matrix metalloproteinase degradation of extracellular matrix: biological consequences
Shapiro, S. D. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80035-5 · Cited by 716
Matrix metalloproteinases in skin
Kähäri, V., & Saarialho‐Kere, U. (1997) · Experimental Dermatology · doi:10.1111/j.1600-0625.1997.tb00164.x · Cited by 607
Hotary, K., Allen, E., Punturieri, A., Yana, I., & Weiss, S. J. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.149.6.1309 · Cited by 594
Matrix Metalloproteinase-9 in Lung Remodeling
Atkinson, J. J., & Senior, R. M. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2002-0166tr · Cited by 587
Self-citationSabeh, F., Ota, I., Holmbeck, K., Birkedal-Hansen, H., Soloway, P., Balbin, M., Lopez-Otin, C., Shapiro, S., Inada, M., Krane, S., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408028 · Cited by 586
Gelatinase B functions as regulator and effector in leukocyte biology
Opdenakker, G., Van den Steen, P. E., Dubois, B., Nelissen, I., Van Coillie, E., Masure, S., Proost, P., & Van Damme, J. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.6.851 · Cited by 553
“For instance, in one study, no defect in neutrophil chemotaxis was found [47], whereas in other investigations, direct [41] or indirect evidence [37] for reduced (neutrophil) chemotaxis was obtained.”
BackgroundCritical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
Zucker, S., Cao, J., & Chen, W.-T. (2000) · Oncogene · doi:10.1038/sj.onc.1204097 · Cited by 550
Noble, L. J., Donovan, F., Igarashi, T., Goussev, S., & Werb, Z. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-17-07526.2002 · Cited by 494
Self-citationMatrix metalloproteinases in inflammation
Nissinen, L., & Kähäri, V.-M. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.03.007 · Cited by 444
Gelatinase B: a tuner and amplifier of immune functions
Opdenakker, G., Van den Steen, P. E., & Van Damme, J. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02023-3 · Cited by 402
The Serpin α1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo
Liu, Z., Zhou, X., Shapiro, S. D., Shipley, J. M., Twining, S. S., Diaz, L. A., Senior, R. M., & Werb, Z. (2000) · Cell · doi:10.1016/s0092-8674(00)00087-8 · Cited by 388
Self-citationMatrix metalloproteinases in repair
Parks, W. C. (1999) · Wound Repair and Regeneration · doi:10.1046/j.1524-475x.1999.00423.x · Cited by 382
Cauwe, B., Van den Steen, P. E., & Opdenakker, G. (2007) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230701340019 · Cited by 381
Matrix metalloproteinases in lung biology
Parks, W. C., & Shapiro, S. D. (2000) · Respiratory Research · doi:10.1186/rr33 · Cited by 380
Huang, S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.15.1134 · Cited by 349
Johnson, C., & Galis, Z. S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000100402.69997.c3 · Cited by 314
Castaneda, F. E., Walia, B., Vijay–Kumar, M., Patel, N. R., Roser, S., Kolachala, V. L., Rojas, M., Wang, L., Oprea, G., Garg, P., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.017 · Cited by 267
Dubois, B., Masure, S., Hurtenbach, U., Paemen, L., Heremans, H., van den Oord, J., Sciot, R., Meinhardt, T., Hämmerling, G., Opdenakker, G., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6886 · Cited by 262
Matrix Metalloproteinase-9 Deficiency Impairs Host Defense against Abdominal Sepsis
Renckens, R., Roelofs, J. J. T. H., Florquin, S., de Vos, A. F., Lijnen, H. R., van’t Veer, C., & van der Poll, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3735 · Cited by 258
Neutrophil Gelatinase B and Chemokines in Leukocytosis and Stem Cell Mobilization
Starckx, S., Van den Steen, P. E., Wuyts, A., Van Damme, J., & Opdenakker, G. (2002) · Leukemia & Lymphoma · doi:10.1080/10428190290005982 · Cited by 49
Metadata
- Authors
- Liu, Z., Michael Shipley, J., Vu, T. H., Zhou, X., Diaz, L. A., Werb, Z., & Senior, R. M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1998-08-03
- Volume
- 188
- Issue
- 3
- Pages
- 475-482
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2059450459
- Cited by
- 243
- References
- 1
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.